Magnetic liposomes for colorectal cancer cells therapy by high-frequency magnetic field treatment

• Published in: Nanoscale research letters 2014-09, Vol.9 (1), p.497-497, Article 497
• Main Authors: Hardiansyah, Andri, Huang, Li-Ying, Yang, Ming-Chien, Liu, Ting-Yu, Tsai, Sung-Chen, Yang, Chih-Yung, Kuo, Chih-Yu, Chan, Tzu-Yi, Zou, Hui-Ming, Lian, Wei-Nan, Lin, Chi-Hung
• Format: Article
• Language: English
• Subjects: Chemistry and Materials Science; Colorectal cancer; EMN Meeting; Materials Science; Molecular Medicine; Nano Express; Nanochemistry; Nanoscale Science and Technology; Nanotechnology; Nanotechnology and Microengineering
• ISSN: 1931-7573; 1556-276X; 1556-276X
• DOI: 10.1186/1556-276X-9-497

In this study, we developed the cancer treatment through the combination of chemotherapy and thermotherapy using doxorubicin-loaded magnetic liposomes. The citric acid-coated magnetic nanoparticles (CAMNP, ca. 10 nm) and doxorubicin were encapsulated into the liposome (HSPC/DSPE/cholesterol = 12.5:1:8.25) by rotary evaporation and ultrasonication process. The resultant magnetic liposomes ( ca. 90 to 130 nm) were subject to characterization including transmission electron microscopy (TEM), dynamic light scattering (DLS), X-ray diffraction (XRD), zeta potential, Fourier transform infrared (FTIR) spectrophotometer, and fluorescence microscope. In vitro cytotoxicity of the drug carrier platform was investigated through 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay using L-929 cells, as the mammalian cell model. In vitro cytotoxicity and hyperthermia (inductive heating) studies were evaluated against colorectal cancer (CT-26 cells) with high-frequency magnetic field (HFMF) exposure. MTT assay revealed that these drug carriers exhibited no cytotoxicity against L-929 cells, suggesting excellent biocompatibility. When the magnetic liposomes with 1 μM doxorubicin was used to treat CT-26 cells in combination with HFMF exposure, approximately 56% cells were killed and found to be more effective than either hyperthermia or chemotherapy treatment individually. Therefore, these results show that the synergistic effects between chemotherapy (drug-controlled release) and hyperthermia increase the capability to kill cancer cells.